Healthcare private equity firms Hildred Capital Management, LLC (“Hildred”) and Bourne Partners Strategic Capital (“Bourne”), together with The Emerson Group (“Emerson”), have launched Carlin Consumer Health (“Carlin”) to establish a preeminent consumer health business and to acquire leading over-the-counter (“OTC”) brands. Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers. OTC products offer 24/7 access to important treatment solutions and deliver significant value to the US healthcare system as the first line of healthcare defense for millions of Americans. They are convenient and effective solutions for self-treating conditions, such as the common cold, allergies, gastrointestinal issues, and pain. Carlin recently acquired of Zegerid OTC® (“Zegerid”) from Bayer AG (“Bayer”). Zegerid is an OTC proton pump inhibitor used for the treatment of frequent heartburn with a unique dual-ingredient, branded combination that provides 24-hour relief from one daily capsule. Carlin plans to launch new consumer awareness campaigns using print and digital media as well as promotional programs with the top US retailers.
